Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Price:
60.4
CNY
-1.05%
Market Closed
Market Cap:
¥10.7B
Balance Sheet
Balance Sheet Decomposition
Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Balance Sheet Decomposition is not available for
Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Balance Sheet
Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Currency: CNY
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
272
|
364
|
404
|
1 055
|
1 036
|
823
|
768
|
965
|
|
| Cash |
272
|
364
|
404
|
1 055
|
1 017
|
822
|
768
|
965
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
19
|
1
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
570
|
454
|
516
|
742
|
452
|
|
| Total Receivables |
57
|
105
|
153
|
170
|
149
|
192
|
182
|
296
|
|
| Accounts Receivables |
52
|
91
|
119
|
121
|
112
|
137
|
120
|
177
|
|
| Other Receivables |
5
|
15
|
34
|
48
|
37
|
55
|
62
|
119
|
|
| Inventory |
55
|
52
|
60
|
84
|
104
|
141
|
161
|
190
|
|
| Other Current Assets |
24
|
8
|
14
|
15
|
36
|
37
|
30
|
25
|
|
| Total Current Assets |
408
|
529
|
631
|
1 894
|
1 779
|
1 709
|
1 883
|
1 929
|
|
| PP&E Net |
163
|
217
|
310
|
588
|
921
|
1 170
|
1 282
|
1 264
|
|
| PP&E Gross |
163
|
217
|
310
|
588
|
921
|
1 170
|
1 282
|
1 264
|
|
| Accumulated Depreciation |
90
|
115
|
137
|
168
|
196
|
251
|
317
|
394
|
|
| Intangible Assets |
15
|
36
|
35
|
34
|
42
|
77
|
84
|
109
|
|
| Long-Term Investments |
2
|
3
|
3
|
3
|
3
|
49
|
81
|
81
|
|
| Other Long-Term Assets |
5
|
5
|
8
|
13
|
31
|
12
|
3
|
3
|
|
| Total Assets |
592
N/A
|
790
+33%
|
987
+25%
|
2 531
+156%
|
2 775
+10%
|
3 018
+9%
|
3 347
+11%
|
3 400
+2%
|
|
| Liabilities | |||||||||
| Accounts Payable |
10
|
32
|
51
|
123
|
158
|
148
|
135
|
109
|
|
| Accrued Liabilities |
16
|
24
|
44
|
58
|
57
|
72
|
63
|
80
|
|
| Short-Term Debt |
0
|
1
|
10
|
42
|
70
|
117
|
227
|
117
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
|
| Other Current Liabilities |
105
|
136
|
172
|
163
|
147
|
193
|
232
|
287
|
|
| Total Current Liabilities |
130
|
193
|
277
|
385
|
433
|
529
|
661
|
596
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
40
|
36
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
|
| Other Liabilities |
17
|
15
|
13
|
50
|
51
|
43
|
41
|
68
|
|
| Total Liabilities |
147
N/A
|
208
+41%
|
290
+40%
|
436
+50%
|
484
+11%
|
573
+19%
|
743
+30%
|
702
-6%
|
|
| Equity | |||||||||
| Common Stock |
90
|
90
|
90
|
120
|
120
|
120
|
120
|
177
|
|
| Retained Earnings |
134
|
269
|
356
|
531
|
728
|
880
|
1 041
|
1 209
|
|
| Additional Paid In Capital |
222
|
223
|
251
|
1 444
|
1 444
|
1 444
|
1 444
|
1 388
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
76
|
|
| Total Equity |
445
N/A
|
582
+31%
|
697
+20%
|
2 095
+200%
|
2 292
+9%
|
2 444
+7%
|
2 603
+6%
|
2 698
+4%
|
|
| Total Liabilities & Equity |
592
N/A
|
790
+33%
|
987
+25%
|
2 531
+156%
|
2 775
+10%
|
3 018
+9%
|
3 347
+11%
|
3 400
+2%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
90
|
90
|
90
|
120
|
120
|
177
|
176
|
177
|
|
Switch to:
Switch to:
See Also
Discover More
